Protocol Ledger

NCT06712355 · Phase III · RECRUITING

Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer

Interventional Phase III clinical trial protocol NCT06712355 sponsored by BioNTech in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2025-02-03 Enrollment: 621 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT06712355
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)621 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)0 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06712355
Protocol FieldVerified Registry Value
NCT IdentifierNCT06712355
Consolidated Lead SponsorBioNTech
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment621 participants (ESTIMATED)
Registered Start Date2025-02-03
WhyStopped ClassificationNot Stopped

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI